Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI-HF and Val-HeFT trials-Reference-Cited by-同舟云学术

Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI-HF and Val-HeFT trials

Published:2015-02-22 Issue:4 Volume:17 Page:424-433
ISSN:1388-9842
Container-title:European Journal of Heart Failure
language:en
Short-container-title:Eur J Heart Fail

Author:

Rossignol Patrick¹²³,Masson Serge⁴,Barlera Simona⁴,Girerd Nicolas¹²³,Castelnovo Angelo⁴,Zannad Faiez¹²³,Clemenza Francesco⁵,Tognoni Gianni⁶,Anand Inder S.⁷,Cohn Jay N.⁸,Anker Stefan D.⁹¹⁰,Tavazzi Luigi¹¹,Latini Roberto⁴,

Affiliation:

1. INSERM; Centre d'Investigations Cliniques-Plurithématique 1433; Nancy France

2. Université de Lorraine; France

3. INSERM U1116; Nancy France

4. Department of Cardiovascular Research; IRCCS-Istituto di Ricerche Farmacologiche Mario Negri; Milan Italy

5. Heart Failure Unit-ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione); Palermo Italy

6. Fondazione Mario Negri Sud; Santa Maria Imbaro Italy

7. Veterans Affairs Medical Center and University of Minnesota; Minneapolis MN USA

8. Cardiovascular Division; University of Minnesota Medical School; Minneapolis MN USA

9. Department of Innovative Clinical Trials; University Medical Centre Göttingen; Göttingen Germany

10. Institute of Diabetes for Older People (IDOP); University of Bedfordshire; UK

11. GVM Hospitals of Care and Research; E.S Health Science Foundation; Cotignola Italy

Funder

Reagents for measuring NT-proBNP in Val-HeFT and GISSI-HF were kindly provided by Roche Diagnostics GmbH.

the European Commissionâ€™s Seventh Framework Programme

The GISSI-HF trial was supported by grants from SocietÃ Prodotti Antibiotici (SPA, Italy), Pfizer, Sigma Tau and AstraZeneca.

The Val-HeFT trial was funded by Novartis Pharmaceuticals (Switzerland).

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine

Reference30 articles.

1. The relationship between obesity and mortality in patients with heart failure;Horwich;J Am Coll Cardiol,2001

2. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss;Lavie;J Am Coll Cardiol,2009

3. Wasting as independent risk factor for mortality in chronic heart failure;Anker;Lancet,1997

4. Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study;Anker;Lancet,2003

5. Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (charm) programme;Pocock;Eur Heart J,2008

Cited by 111 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The therapeutic effect of NRF2 activator, ezetimibe, in cardiac cachexia;Fundamental & Clinical Pharmacology;2024-07-15

2. Controversies and Conundrums in Cardiac Cachexia;JACC: Heart Failure;2024-05

3. Prognostic influence of weight loss on overweight/obese young heart failure patients;Saudi Medical Journal;2024-04

4. Malnutrition as a prognostic factor for 2‐year mortality in hospitalized patients in Norway: A matched cohort study;Journal of Parenteral and Enteral Nutrition;2024-03-13

5. Association of weight loss with cardiovascular or all-cause mortality in patients with heart failure: A meta-analysis;International Journal of Obesity;2024-02-05